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was estimated by time-adjusted Cox proportional hazards
regression.
RESULTS Among 8,582 “all-comers” patients who underwent suc-
cessful PCI with DES in the ADAPT-DES study, PDB occurred in 535/
8,577 hospital survivors (6.2%) at a median time of 300 days (inter-
quartile range: 130 to 509 days) after hospital discharge. Gastroin-
testinal bleeding (61.7%) was the most frequent source of PDB.
Predictors of PDB included older age, lower baseline hemoglobin,
lower platelet reactivity on clopidogrel, and use of chronic oral anti-
coagulation therapy. PDB was associated with higher crude rates of
all-cause mortality (13.0% vs. 3.2%; p<0.0001; Figure). Following
multivariable adjustment, PDB was strongly associated with 2-year
mortality (HR: 5.03; 95% CI: 3.29–7.66; p<0.0001), with an effect
size greater than that of post-discharge myocardial infarction (PDMI)
(HR: 1.92; 95% CI: 1.18–3.12; p¼0.009).
CONCLUSIONS Following successful PCI with DES in an unrestricted
patient population, PDB is not uncommon, and has a strong rela-
tionship with subsequent all-cause mortality, greater that that asso-
ciated with PDMI. Efforts to reduce PDB may further improve
prognosis after successful DES implantation.
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BACKGROUND The PE Plus Post-Approval Study (PE Plus PAS) was
designed to examine long-term outcomes among patients treated
with advanced generation, everolimus-eluting, platinum chromium
PROMUS Element stents (Boston Scientiﬁc, Marlborough, MA) in
unselected patients treated in routine practice. This is the ﬁrst
report of 2-year results from this large multicenter post-approval
study.
METHODS PE Plus PAS was a prospective, open-label, multicenter
observational study enrolling 2684 patients at 52 sites in the US.
Follow-up was at 30 days, 6 months, and 1 year, and will continue
annually through 5 years. The primary endpoint was 12-monthcardiac death or myocardial infarction (CD/MI) in ‘PLATINUM-like’
patients who received PROMUS Element Plus in PE Plus PAS, PE
PROVE and patients from the PLATINUM Workhorse/Small Vessel
trials compared to a performance goal (3.2%) derived from out-
comes in SPIRIT IV and the PLATINUM trial. The PLATINUM-like
patient cohort was deﬁned as all patients that met the criteria for
enrollment in the PLATINUM trial. A Clinical Events Committee
adjudicated major adverse cardiac events and their relatedness to
the study stent.
RESULTS In the PE Plus PAS, 30% of patients were female, mean
age was 64 years, 37% had medically treated diabetes, and more
than three-quarters were treated for hyperlipidemia and hyperten-
sion. At baseline, mean lesion length was 1710 mm and mean
reference vessel diameter was 2.90.5 mm (in 3595 treated lesions).
PLATINUM-like patients accounted for 29% of the overall PE Plus
PAS patient population. For the primary endpoint, 12-month CD/MI
in PLATINUM-like patients was 1.8% (33/1855) with a upper 1-sided
95% conﬁdence interval of 2.3%, which was signiﬁcantly less than
the prespeciﬁed performance goal of 3.2% (Pnoninferiority<0.001).
In the overall PE Plus population, 12-month major adverse cardiac
events were low.
CONCLUSIONS The 2-year results from the PE Plus PAS will be
available for presentation for the ﬁrst time at TCT 2015 and will show
favorable performance and safety for the PROMUS Element Plus
everolimus-eluting stent at 2 years in an unselected patient
population.
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BACKGROUND The beneﬁt on prognosis after successful recanaliza-
tion of chronic total occlusion (CTO) lesions is uncertain.
METHODS A total of 1173 consecutive patients (mean age 60 years,
82.7% men) with CTOs of native coronary vessels in which per-
cutaneous coronary intervention (PCI) was attempted was enrolled
from March 2003 and May 2014. All successful procedures
(1004 patients, 85.6%) were performed by drug-eluting stent
implantation.
RESULTS During a median of 4.6-year of follow-up, the cumulative
incidence of all-cause death was not signiﬁcantly different between
the successful and unsuccessful CTO-PCI (8.0% vs. 7.1%, P ¼ 0.83).
The cumulative rate of target vessel revascularization (TVR) and
coronary artery bypass grafting (CABG) was remarkably less in
patients with successful PCI compared with those with unsuc-
cessful PCI (TVR; 4.4% vs. 20.9%, P < 0.001, CABG; 0.4% vs.
16.7%, P < 0.001). The adjusted risks of all-cause death (hazard
ratio [HR] 1.19, 95% conﬁdence interval [CI] 0.59 – 2.43, P ¼ 0.62)
and the composite of death or myocardial infarction ([MI], HR 1.06,
95% CI 0.56 – 2.03, P ¼ 0.96) remained comparable between
groups, whereas the adjusted risk of TVR and CABG was signiﬁ-
cantly higher in patients with unsuccessful CTO PCI. Among 879
subjects who eventually had a complete revascularization state for
the non-CTO vessels, the risks of death or the composite of death
or MI were not different between patients who further underwent
successful recanalization of the remaining CTO and those who
did not. This ﬁnding was consistent regardless of whether the
patient had a multi-vessel disease including CTO or only had a
single CTO.
CONCLUSIONS Successful CTO-PCI compared with unsuccessful PCI
was not associated with lesser risk for 4.6-year mortality, but was
associated with signiﬁcantly less subsequent CABG.
